Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ivosidenib or enasidenib added to intensive chemotherapy in newly diagnosed IDH1/IDH2-mutated AML or MDS
ACTRN12619001031156Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 cohorts), sponsored by HOVON. Primary endpoint: Event-free survival. Started Oct 2020; status: active, not recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12619001031156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001031156.